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2ABSTRACT
Background: Thioredoxins (Trx) are small redox proteins that function as general
protein disulfide reductases and regulate several cellular processes such as
transcription factor DNA binding activity, apoptosis and DNA synthesis. In
mammalian organisms, thioredoxins are generally ubiquitously expressed in all
tissues with the exception of Sptrx which is specifically expressed in sperm cells
(Miranda-Vizuete et al. 2001).
Results: We report here the identification and characterization of a novel
member of the thioredoxin family, the second with a tissue-specific distribution in
human sperm, termed Sptrx-2. The Sptrx-2 ORF encodes for a protein of 588 amino
acids with two different domains: an N-terminal thioredoxin domain encompassing
the first 105 residues and a C-terminal domain composed of three repeats of a NDP
kinase domain. The Sptrx-2 gene spans about 51 kb organized in 17 exons and maps
at locus 7p13-14. Sptrx-2 mRNA is exclusively expressed in human testis, mainly in
primary spermatocytes while Sptrx-2 protein expression is detected from the
pachytene spermatocytes stage onwards, peaking at round spermatids stage.
Recombinant full-length Sptrx–2 expressed in bacteria displayed neither thioredoxin
nor NDP kinase enzymatic activity.
Conclusions: The sperm specific expression of Sptrx-2, together with its
chromosomal assignment to a position reported as a potential locus for flagellar
anomalies and male infertility phenotypes such as primary ciliary dyskinesia
suggests that it might be a novel component of the human sperm axonemal
organization.
3INTRODUCTION
Thioredoxins (Trx) are small ubiquitous proteins that are conserved in all
organisms through evolution. They are characterized by the sequence of their highly
conserved active site Cys-Gly-Pro-Cys (CGPC) and participate in different cellular
mechanisms, mainly redox reactions by the reversible oxidation of their active site
from the dithiol form to disulfide (Arner & Holmgren 2000; Powis & Montfort 2001).
To be active, thioredoxins must be reduced and this state is maintained by the
flavoenzyme thioredoxin reductase (TrxR) at expense of the reducing power of
NADPH, thus forming the so-called thioredoxin system (Holmgren & Björnstedt
1995). All organisms so far investigated contain several thioredoxins. Thus, E. coli has
two thioredoxins, both cytosolic, and the lower eukaryote Saccharomyces cerevisiae has
three, two cytosolic and one mitochondrial (Grant 2001; Laurent et al. 1964; Miranda-
Vizuete et al. 1997a; Pedrajas et al. 1999). The increasing complexity of higher
eukaryotes is also reflected in the thioredoxin family. For instance, a homology
search in Caernohabditis elegans and Drosophila melanogaster genomes identify up to
eight proteins containing the active site WCGPC. The number of thioredoxins in
mammalian organisms is lower although it is expected to increase once the human
genome sequence has been fully searched. Currently, in humans there are three
ubiquitous forms, Trx-1, Trx-2 and Txl-1 and only one tissue specific Sptrx expressed
in spermatozoa (Holmgren & Björnstedt 1995; Miranda-Vizuete et al. 2000; Miranda-
Vizuete et al. 1998; Miranda-Vizuete et al. 2001).
Initially discovered as an electron donor for ribonucleotide reductase, an
essential enzyme in DNA synthesis, many other functions have since then been
ascribed to thioredoxins. They reduce other metabolic enzymes like PAPS reductase
or methionine sulfoxide reductase, regulate transcription factor DNA binding
4activity, act as antioxidant molecules, modulate apoptosis and have also been
implicated in many pathological situations (Powis & Montfort 2001).
Based on protein sequence organization two distinct groups can be identified
within the thioredoxin family. Group I includes those proteins that exclusively
encode a thioredoxin domain while group II is composed of fusion proteins of
thioredoxin domains plus additional domains. Among those belonging to group I are
E. coli Trx-1, the three yeast thioredoxins or mammalian Trx-1 and Trx-2 (Grant 2001;
Holmgren & Björnstedt 1995; Laurent et al. 1964; Spyrou et al. 1997). Examples of
group II thioredoxins are E. coli Trx-2, that has an N-terminal extension that
resembles the structure of a zinc finger domain (Miranda-Vizuete et al. 1997a) or the
DLC14 and DLC16 of Chlamydomonas reinhardtii flagellar outer dynein arm that
possess a thioredoxin domain followed by a C-terminal extension of unknown
function (Patel-King et al. 1996). Also belonging to group II are mammalian Txl-1 and
Sptrx which have additional domains displaying no homology with any other
protein in the databases (Miranda-Vizuete et al. 1998; Miranda-Vizuete et al. 2001).
Another member of group II is sea urchin IC1 protein, a sperm outer dynein arm
intermediate chain which is composed of an N-terminal thioredoxin domain
followed by three nucleoside diphosphate (NDP) kinase domains (Ogawa et al. 1996).
NDP-kinase represents a large family of structurally and functionally conserved
proteins from bacteria to humans also known as nm23 that, in general, catalyzes the
transfer of g-phosphates between nucleosides and deoxynucleoside di- and tri-
phosphates, therefore playing a pivotal role in maintaining a balanced pool of
nucleotides (Postel et al. 2000). In humans, eight different members of the nm23
family have been reported to date (nm23-H1 to H8), and as with the thioredoxin
family, nm23 proteins can also be classified into two groups based on sequence
alignment and phylogenetic analysis (Lacombe et al. 2000). Group I is composed of
5nm23-H1 to H4, and is characterized by a similar genomic organization, the
formation of hexamers of identical subunits and the classical enzymatic activity of
NDP kinases. Group II encompasses nm23-H5 to H8 genes which are defined by a
more divergent sequence, have an NDP kinase active site sequence that is not strictly
conserved and have considerable variation in the lengths of their N- and C-terminal
domains (Lacombe et al. 2000). Besides the kinase function, human nm23 proteins
have been implicated in cell growth, tumor suppression metastasis and development
(Lombardi et al. 2000). In addition, nm23-H2 has been shown to be the transcription
factor Puf for the proto-oncogene c-myc (Postel et al. 1993). Most human nm23
proteins are found in cytosol, although nm23-H4 is shown to be a mitochondrial
enzyme (Lacombe et al. 2000; Milon et al. 2000). Furthermore, nm23-H5, H6 and H8
have been shown to have a tissue-specific distribution, mostly expressed in human
testis (Lacombe et al. 2000; Munier et al. 1998). We have described a similar situation
in the thioredoxin family and have also identified mitochondrial and sperm specific
members (Miranda-Vizuete et al. 2001; Spyrou et al. 1997).
We report here the characterization of a novel member of the thioredoxin family, the
second with a tissue specific distribution in human testis, termed Sptrx-2 based on its
expression pattern in spermatozoa. The Sptrx-2 sequence has been independently
deposited in public databases (GenBank entry NM_016616) as a member of the nm23
family (nm23-H8) due to the presence of three NDP kinase domains located at the C-
terminus of the thioredoxin domain. Thus, Sptrx-2 must be classified as a member of
the group II of thioredoxins. Sptrx-2 displays high homology with sea urchin IC1
(intermediate chain-1) protein, a component of the sperm axonemal outer dynein
arm complex (Ogawa et al. 1996). Taken together, Sptrx-2 appears to be a new
component of the human sperm axoneme architecture and its possible role in human
sperm motility and fertility is discussed.
6RESULTS
cDNA cloning, sequence analysis, genomic organization and chromosomal
localization of human Sptrx-2 gene. By sequence comparison we found that
Genbank entry AF202051 encoded a putative novel human thioredoxin-like
sequence. As no information regarding tissue expression was stated in this entry we
performed a BLAST search in Genbank EST database to determine which cDNA
library we should use to confirm AF202051 sequence. The search resulted in the
identification of three matches from testis, total fetus and male germ cell tumors,
respectively (GenBank entries: AL043096, AI077399 and AW590130). Therefore, we
designed specific primers based on AF202051 sequence and performed 5’- and 3’-
RACE PCR analysis in a human testis cDNA library to clone the full-length cDNA
sequence of this novel protein. The complete sequence of the cDNA obtained consists
of an ORF of 1767 bp, a 5’-UTR of 70 bp including two stop codons in frame and a 3’-
UTR of 166 bp before the poly(A)+ tail (Fig. 1). Human Sptrx-2 ORF encodes a protein
of 588 amino acids with an estimated molecular mass of 67.3 kDa and a pI of 4.82. It
is interesting that Sptrx-1 pI (Miranda-Vizuete et al. 2001) is identical to that of Sptrx-
2. Analysis of the human Sptrx-2 sequence identified two distinct domains: an N-
terminal domain (comprising the first 105 residues) similar to thioredoxins and a C-
terminal domain composed of three tandemly repeated NDP kinase domains (Fig.
2A). Interestingly, the Sptrx-2 protein domain organization resembles the one of IC1,
an outer dynein arm of sea urchin axoneme (Ogawa et al. 1996). Regarding the N-
terminal thioredoxin domain, some of the structural amino acids that are conserved
in previously characterized mammalian thioredoxins like Asp-26, Trp-31, Pro-40 or
Gly-91 (numbers referred to those of human Trx-1) are also conserved in Sptrx-2 (Fig.
2B). However, other important residues shown to be essential for catalysis,
7maintenance of three-dimensional structure or protein-protein interactions are
changed, for instance Phe-11, Ala-29, Asp-58 or Lys-81 (Eklund et al. 1991). The
alignment of all known human thioredoxins was used to perform a phylogenetic
analysis including a novel thioredoxin-like protein, named Txl-21. As shown in
Figure 3A and 3B, mitochondrial thioredoxin (Trx-2) separates from the rest of the
human thioredoxins quite early in evolution and the remaining members are
clustered into three different groups: Trx-1 and Sptrx-1, Sptrx-2 and Txl-2, and finally
Txl-1. Sptrx-1 is a retrogene originating from human Trx-1 mRNA; whereas, Sptrx-2
and Txl-2 have identical intron/exon organization1 suggesting they have originated
from a genomic duplication event. Txl-1 is placed alone in an independent branch.
Additionally, the Sptrx-2 C-terminal domain consists of three repeats of an NDP
kinase domain. The first domain (NDPk-A) is truncated while the second and third
(NDPk-B and NDPk-C) are complete (Fig. 2A). As noted previously, Sptrx-2 has also
been reported as a novel member of the NDP kinase family of proteins, termed
nm23-H8. However, no published report on this protein has been done except a brief
mention in a review (Lacombe et al. 2000). In this review, a protein alignment and
phylogenetic analysis of all human NDP kinase domains is done, showing that the
Sptrx-2 NDPk-B and NDPk-C domains belong to NDP kinase group II.
In X-ray crystallography and site-directed mutagenesis studies, nine residues
essential for catalysis and stability of nm23 proteins have been identified (Lacombe et
al. 2000; Lombardi et al. 2000). Surprisingly, the Sptrx-2 NDPk-B domain only has two
out of nine conserved residues while the NDPk-C domain has seven conserved
residues regarded as crucial for enzymatic activity. Furthermore, the sequence of the
active site in the NDPk-B domain (NXXY) is different from the remaining nm23
proteins (NXXH) where X can be any residue (Fig. 2A).
                                                
1  Antonio Miranda-Vizuete t al., manuscript in preparation.
8Comparison of the protein sequence with PROSITE database (Bairoch et al.
1997) identified, along with the above mentioned thioredoxin and NDP kinase
domains, several potential phosphorylation sites for protein kinases CKI, CKII, GSK3
and PKC with only one potential site for PKA. In addition, a highly scored PEST
sequence for proteasome-dependent degradation centered at position 242 (Fig. 1).
A homology search in GenBank identified Sptrx-2 genomic region in the
genomic BAC clone AC018634. Sptrx-2 gene spans about 51 kb and is organized into
17 exons and 16 introns all of them conforming to the GT/AG rule (Table 1). Finally,
the BAC clone AC018634 has been mapped to human chromosome 7p13-14, between
the markers D7S485 and D7S528, by PCR screening of a human-rodent radiation
panel.
Tissue and cellular expression of human Sptrx-2 mRNA. Multiple-tissue
Northern blots were used to determine the size and tissue distribution of human
Sptrx-2 mRNAs using the ORF as the probe. Human Sptrx-2 mRNA was only
detected in human testis as a single band of approximately 2.4 kb in good agreement
with the size of the cloned cDNA (Fig. 4). It should be noted that a very long
exposure of the blots was required to identify the hybridization signal which
suggests that Sptrx-2 mRNA might not be expressed at high levels, consistent with
the low number (three) of matching EST sequences in the human database. To
evaluate the possibility that Sptrx-2 mRNA could be expressed in other tissues not
present in these blots, we also screened an RNA dot blot containing poly(A)+ RNAs
from 50 different human tissues. Among the tissues examined, hybridization signal
was observed only in testis mRNA (data not shown). The testis specific mRNA
expression obtained by Northern blot analysis is in agreement with that of Mehus
and Lambeth obtained by RT-PCR (Lacombe et al. 2000).
9To further investigate the expression pattern of Sptrx-2 mRNA, in situ
hybridization was performed in human testis sections showing that it is expressed in
primary spermatocytes and round spermatids with no signal in the remainder of the
testicular cells (Fig. 5). Similar results have been obtained using mouse Sptrx-2 cDNA
in mouse testis sections (M. Pelto-Huikko and A Miranda-Vizuete, unpublished
results). This expression pattern slightly differs from that of Sptrx-1 mRNA which is
mainly found in round and elongating spermatids (Miranda-Vizuete et al. 2001) and
is also consistent with the three Sptrx-2 matches in GenBank EST database in testis,
male germ cell tumor and total fetus. Hybridization of human Sptrx-2 cDNA probe
in human tissues other than testis resulted in no signal (data not shown).
Expression and enzymatic activity of human Sptrx-2 protein. Recombinant
human Sptrx-2 migrated in SDS-PAGE at 67 kDa size in good agreement with its
theoretical size while a truncated form of Sptrx-2 expressing only the N-terminal
thioredoxin domain migrated approximately at 12 kDa (Fig. 6 inset). Members of the
NDP kinase family have been described to be hexamers in their native conformations
(Lacombe et al. 2000). To evaluate whether this was also the case for Sptrx-2 we
performed a gel filtration chromatography and found that the protein migrates as a
monomer (Fig. 6).
Enzymatic activity of thioredoxins is usually assayed by their capacity to reduce
the disulfide bonds of insulin using either DTT as artificial reductant or NADPH and
thioredoxin reductase as a more physiological reducing system (Arner & Holmgren
2000). We were unable to detect any Sptrx-2 enzymatic activity using calf thymus
thioredoxin reductase and NADPH with either the full-length protein or the
truncated form (data not shown). However, when using DTT as reductant we were
able to detect activity with the truncated form expressing only the thioredoxin
domain. When compared with human Trx-1 used as control, truncated Sptrx-2
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displayed a similar enzymatic activity profile although at a 1:5 molar ratio and with a
marked latency phase (Fig. 7). Taken together, these data suggest that Sptrx-2 is not
an efficient protein disulfide reductase in vitro.
NDP kinases catalyze the transfer of a terminal phosphate residue from NTPs to
NDPs according to a ping-pong mechanism. The first step of this reaction consists of
the autophosphorylation of the enzyme at a conserved histidine of the active site
(Biondi et al. 1996; Lecroisey et al. 1995). As noted above, the NDPk-C domain of
Sptrx-2 has the typical active site sequence NXXH while the NDPk-B domain has a
substitution of the histidine residue by a tyrosine, which might also be
phosphorylated (Fig. 2A). However, Sptrx-2 is unable to undergo
autophosphorylation under the same experimental conditions that allowed positive
control yeast NDP kinase autophosphorylation (data not shown) (Milon et al. 2000).
To assess the possibility that Sptrx-2 could display enzymatic activity in an in
vivo system we overexpressed human Sptrx-2 in HEK293 cells by transient
transfections experiments. Cells overexpressing full-length Sptrx-2 did not show
significant differences on enzymatic activity over the control values, due to the high
levels of endogenous thioredoxin activity (data not shown).
Tissue expression and cellular and subcellular localization of human Sptrx-2
protein. Affinity-purified antibodies were used to study the expression pattern of
human Sptrx-2 protein in different human tissues and cell lines. As shown in Figure
8A, only human testis and sperm extracts expressed Sptrx-2 as a band of
approximately 67 kDa in good agreement with the migration of the recombinant
protein in SDS gels. No signal was detected in any other tissue or cell line used as
control, including those harbouring flagella tissues like lung and trachea. The
antibodies also recognized a band of similar size in rat, mouse and bull testis extracts
(data not shown). To address the question of whether Sptrx-2 protein distribution
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paralleled the mRNA expression, we performed immunohistochemical analysis in
human testicular sections that revealed that Sptrx-2 expression was restricted to
spermiogenesis, starting at the pachytene spermatocytes level and peaking at the
round and elongating spermatid stage (Figure 8B). Other testicular cell types like
spermatogonia, Sertoli and Leydig cells were devoid of signal. Immunofluorescence
analysis of human ejaculated spermatozoa identifies Sptrx-2 signal localized from the
caudal  region of the head to the end of the principal piece of sperm tail (Figure 8C).
To determine whether Sptrx-2 protein might be targeted to any subcellular
compartment during spermiogenesis, we constructed plasmid vectors to express it as
a fusion protein carrying GFP at its C-terminus. The plasmid was transiently
transfected into HEK293 cells and the fluorescent fusion protein detected by confocal
microscopy. Cells transfected with the control plasmid expressing only the GFP
protein showed fluorescence in both cytosol and nucleus, as its small size (27 kDa)
allows it to translocate into the nucleus passively (data not shown). The fusion
protein Sptrx-2/GFP showed a clear cytosolic distribution although a weaker
punctuated pattern could also be found in the nucleus (Fig. 9A). When this image
was merged with DNA staining (Fig. 9B) a yellow colour indicating colocalization
was obtained in the perinuclear region and also scattered through the nucleus (Fig.
9C). There was also a dotted yellow pattern in the cytosol, which might correspond
to mitochondria as they also contain DNA. The presence of Sptrx-2 in nucleus is not
likely to be an artefact as a control with Sptrx-1 or Txl-2 GFP fusion constructs had a
clear cytosolic localization with no nuclear fluorescent signal (A. Miranda-Vizuete,
unpublished results) and the subcellular localization of the Sptrx-2/GFP fusion
protein in vivo was similar to that of fixed cells (data not shown). In addition, it is
important to point out that Sptrx-2 sequence analysis on PSORT II program
(http://psort.ims.u-tokyo.ac.jp/form2.html) identified two putative pat7 nuclear
targeting sequences centred at residues 50 (PLFRKLK) and 308 (PDFKKMK),
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respectively (Hicks & Raikhel 1995), and a putative mitochondrial pre-sequence
cleavage site at residue 16 (REVQLQTVINN QS), although the overall prediction is
cytosolic (Gavel & von Heijne 1990). These data might explain the pattern obtained
with the Sptrx-2/GFP fusion protein.
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DISCUSSION
The first form of thioredoxin (now termed Trx-1) was described in E. coli as
early as 1964 (Laurent et al. 1964) whereas the identification of the mammalian mouse
and human homologues had to wait for 25 years (Tagaya et al. 1989; Wollman et al.
1988). Since 1996 our group has been engaged in the search of novel members of the
thioredoxin family of proteins, which resulted in the identification of a mitochondrial
thioredoxin system (Trx-2 and TrxR2), a ubiquitous thioredoxin-like protein of
unknown function (Txl-1) and the first tissue-specific member of the family in human
spermatozoa (Sptrx-1) (Miranda-Vizuete et al. 2000; Miranda-Vizuete et al. 1998;
Miranda-Vizuete et al. 2001). All known thioredoxins fall into two groups depending
on whether they are composed of only a thioredoxin domain, (Trx-1 and Trx-2,
Group I) or have additional domains (Txl-1 and Sptrx-1, Group II). We report here
the identification of the second tissue-specific member of the family, named Sptrx-2,
also in male germ cells.
Sptrx-2 is organized into one N-terminal thioredoxin domain followed by three
NDP kinase domains, the first of them incomplete. A similar protein arrangement
has been described for IC1, a sea urchin protein which has been classified as one of
the three intermediate chains of axonemal outer arm dynein sperm axoneme (Ogawa
et al. 1996). Thus IC1 is also composed of a thioredoxin domain, three tandemly
repeated NDP kinase domains and only differs from Sptrx-2 in a C-terminal part rich
in glutamic acid residues. Sptrx-2 has been proposed to be the human homologue of
IC1 based on sequence similarity (Lacombe et al. 2000). The occurrence of thioredoxin
domains in other flagellar proteins have also been reported in outer arm dynein light
chains DLC14 and DLC16 from Chlamydomonas flagella (Patel-King et al. 1996).
However, to our knowledge, thioredoxin activity has not been properly assayed in
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these flagellar proteins. In our study, we have failed to detect any enzymatic
thioredoxin activity when assaying recombinant full-length Sptrx-2 (expressed in
bacteria) with NADPH and calf thymus thioredoxin reductase or DTT. Only when
expressing the thioredoxin domain alone we were able to detect a significant activity
in the DTT assay. The acquisition of a thioredoxin domain in flagellar proteins occurs
early in evolution and is most likely a consequence of molecular or enzymatic
requirements for a specific function in flagellum movement (Patel-King et al. 1996).
The lack of thioredoxin activity in Sptrx-2 most probably depends on its three-
dimensional structure, not only of the full-length protein but also of the thioredoxin
domain itself that impedes the access of the natural catalyst thioredoxin reductase to
its active site. This implies that another mechanism might operate to maintain Sptrx-2
in an active reduced state. One possible explanation is the newly described TRG, a
fusion protein of a glutaredoxin and a thioredoxin reductase module which is highly
expressed in testis and might function as a reducing system for Sptrx-2 (Sun et al.
2001). Alternatively, phosphorylation is one of the most well–established cellular
mechanisms by which a conformational change in a protein is achieved (Cohen 2000)
and the major regulatory pathway in testis and sperm physiology (Eddy & O´Brien
1994). Sptrx-2 has multiple phosphorylation sites and one might speculate that
phosphorylation of the protein could induce a conformational change that would
make the thioredoxin active site accessible to thioredoxin reductase.
The Sptrx-2 thioredoxin domain is followed by one incomplete (lacking the
active site) and two complete NDP kinase domains at the C-terminus of the protein
(domains A, B and C respectively). NDP kinases catalyze the transfer of g -phosphates
between tri- and diphosphonucleosides and are autophosphorylated as an
intermediate in the reaction (Biondi et al. 1996). This autophosphorylation has been
shown to occur at the N d  position of the conserved histidine of the active site NXXH.
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While the NDPk-C domain has this conserved active site sequence, the B domain
lying in the middle of the tandem has the histidine substituted by a tyrosine residue,
which is also phosphorytable thus suggesting possible novel features in the catalytic
mechanism. As with the thioredoxin activity, we have not been able to identify any
autophosphorylation activity in Sptrx-2, which is also the case of the other NDP
kinase specifically expressed in testis, nm23-H5 (Munier et al. 1998). Taken together,
the lack of both thioredoxin and kinase activities in Sptrx-2 while the structures of
the respective domains are so conserved might suggest that interaction with other
proteins or cofactors is needed for Sptrx-2 to function.
Sptrx-2 protein expression is restricted to spermiogenesis, being detected in
pachytene spermatocytes, round and elongating spermatids within human
seminiferous tubules. In mature human sperm Sptrx-2 is mostly found in the tail,
further supporting the hypothesis of being the human homologue of sea urchin IC1
protein. The synthesis of the sperm cytoskeletal polypeptides, has been shown to
occur in the cytoplasm of spermatids, which is consistent with the expression pattern
obtained for Sptrx-2 and corresponds to the growth of the structures that organize
the sperm tail, including the axoneme (Oko 1998). Taken together, it is reasonable to
assume that Sptrx-2 might be a component of the human sperm axonemal machinery
and therefore be a candidate gene to several male infertility phenotypes.
With this aim we first screened the Mendelian Cytogenetics Network Database
(http://mcndb.imbg.ku.dk/) to determine whether any breakpoint in the region
where Sptrx-2 maps has been reported to be associated with an infertility phenotype.
We found four reported breakpoints mapping at Sptrx-2 locus and, interestingly,
three of them had an associated trait of infertility (accession ID number: 702748,
702844 and 702852). Primary ciliary dyskinesia (PCD) is an autosomal recessive
disorder (OMIM 242650) characterized by a failure of proper ciliary and flagellar
movement whose clinical manifestations are chronic respiratory infections, male
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infertility and situs inversus (Blouin et al. 2000; Cowan et al. 2001). The motility of
cilia and flagella is generated in the axoneme which has been estimated to be
composed of more than 250 polypeptides (Dutcher 1995). The axoneme consists of a
core of 9 peripheral + 2 central microtubule doublets (composed of proteins named
tubulins) connected by outer and inner dynein arms (composed of heavy,
intermediate and light chains) plus other accessory proteins. Electron microscopy
studies of sperm of patients affected by PCD reveal anomalies in both microtubule
and dynein arm organization and as a consequence PCD is a genetically highly
heterogeneous disease (Blouin et al. 2000). Our Northern blot analysis has included,
in addition to testis, other cilia harbouring tissues like trachea, brain or lung;
however, we have failed to detect Sptrx-2 mRNA hybridization in any other tissue
than testis. As all cilia and flagella share the same organization the question arises
whether Sptrx-2 gene might code for a sperm-specific axoneme dynein protein. So
far, dynein proteins are classified into two major groups, cytoplasmic and axonemal
with no further tissue specific distinction (Milisav 1998). However, there is
considerable precedent that similar dynein genes could be expressed either in
somatic tissue or male germ cells as cases describing patients with normal somatic
cilia while defective spermatozoa due to lack of dynein arms or viceversa have been
reported (Phillips et al. 1995 and references therein). Differential gene expression in
somatic or germ tissue axoneme is by no means limited to dynein arms (Neesen et al.
1997; Milisav et al. 1996) as a testis specific a -tubulin has been identified in mice
(Distel et al. 1984). Dynein arm deficiency (DAD) is a subgroup of PCD and a recent
linkage analysis has identified 7p, the region where Sptrx-2 maps, as a potential
genomic region harbouring gene(s) involved in DAD (Blouin et al. 2000). Thus,
similarity with sea urchin IC1, male germ cell specific expression and chromosomal
mapping in candidate regions for male infertility phenotypes suggest that Sptrx-2 is a
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gene coding for a sperm axonemal specific form of dynein arm and therefore a good
candidate for male infertility diseases associated with primary ciliary dyskinesia.
Further work is in progress to decipher the functional role of Sptrx-2 in human
spermatogenesis which will shed more light on the newly discovered subset of
thioredoxin proteins with a testis specific expression.
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EXPERIMENTAL PROCEDURES
cDNA cloning of human Sptrx-2 gene: The Basic Local Alignment Search Tool
(BLAST) (Altschul & Koonin 1998) was used to perform a survey of different
databases at the National Center for Biotechnology Information
(http://www.ncbi.nlm.nih.gov/) to identify new entries encoding potential novel
members of the thioredoxin family. Using human Trx-1 and Trx-2 ORF as bait
(Miranda-Vizuete et al. 1997b; Wollman et al. 1988) we found entry AF202051 to
encode a putative thioredoxin-like sequence. This entry was named nm23-H8 by
virtue of its additional sequence homology to members of the NDP kinase family.
Based on this sequence, the primers F1 (5´-CCTGTTTTGTTAGATAAATGGCAAGC-
3´) and R1 (5´-GTTTTCACAGTATATACTTTAGTTTTCC-3´) were used to amplify
by PCR the Sptrx-2 ORF from a human testis cDNA library (Clontech). The
amplification product was cloned in the pGEM-Teasy vector (Promega) and
sequenced in both directions. The nested forward primers F2 (5´-
GAAGCAAAAGCGGTTGTTAATAGAC-3´) and F3 (5´-
GGAAAACTAAAGTATATACTGTG) and the nested reverse primers R2 (5´-
CTTTGATTATTGATGACTGTCTG-3´) and R3 (5´-
GCTTGCCATTTATCTAACAAAACAGG-3´) were used for 3´- and 5´-RACE,
respectively, in the same library to determine the sequence of the Sptrx-2 UTR.
Northern blot analysis: Human multiple tissue Northern blots with poly(A)+
RNA from different tissues were purchased from Clontech. The human Sptrx-2 ORF
was labelled with [ a -32P]dCTP (Rediprime random primer labeling kit, Amersham)
and hybridized at 42°C overnight in UltrahybTM Solution following the protocol
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provided by Ambion. The blots were also hybridized with human b -actin as a
control.
Expression and purification of human Sptrx-2 recombinant protein. The ORF
encoding human Sptrx-2 was cloned into the BamHI-EcoRI sites of the pGEX-4T-1
expression vector (Pharmacia) and used to transform E. coli BL21(DE3). A single
positive colony was inoculated in 1 liter of LB medium plus ampicillin and grown at
37ºC until A600= 0.5. The production of the fusion protein was induced by addition of
0.5 mM IPTG and growth was continued for another 3.5 h. Overexpressing cells were
harvested by centrifugation and frozen until use. The cell pellet was resuspended in
40 ml 20 mM Tris-HCl, 1 mM EDTA and 150 mM NaCl plus protease inhibitor
cocktail at the concentration recommended by manufacturer (SIGMA). Lysozyme
was added to a final concentration of 0.5 mg/ml with stirring for 30 min on ice. 1%
sarkosyl was added and cells disrupted by 10 min sonication and the supernatant
was cleared by centrifugation at 15,000 x g for 30 min and loaded onto a glutathione
sepharose 4B column (Pharmacia Biotech). Binding to the matrix was allowed to
occur for 2 h at room temperature. Thrombin (5U per mg fusion protein) was used to
remove GST by incubation overnight at 4°C. The resulting protein preparation was
then subjected to ion exchange chromatography using a HiTrap Q column
(Pharmacia Biotech) and human Sptrx was eluted using a gradient of NaCl. For gel
filtration chromatography Sptrx-2 preparation from ion exchange chromatography
was applied to a Superdex G-75 prep. grade column (Amersham Pharmacia Biotech)
under non-denaturing conditions, equilibrated with the same buffer as the protein
preparation. Protein concentration was determined from the absorbance at 280 nm
using a molar extinction coefficient of 47,730 M-1 cm-1. The cloning, overexpression
and purification of the truncated form of human Sptrx-2 (h D Sptrx-2) was identical to
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that described for the full-length protein except that the ion exchange purification
step was not required as the protein eluted in a pure form following thrombin
cleavage.
Enzymatic activity assays. Two different assays were used to determine the
enzymatic activity of human Sptrx-2, both based on the ability of the protein to
reduce insulin disulfide bonds in vitro. In the DTT assay, DTT is used as reductant
and the assay was carried out as previously described (Wollman et al. 1988). Briefly,
25 m l of reaction mixture composed of 40 m l of 1M Tris-HCl pH7.4, 10 m l 0.2 M EDTA
pH 8.0 and 200 m l insulin (10 mg/ml) were added to the different enzyme
preparations in a final volume of 200 m l. The reaction was initiated by adding 1 m l of
0.1 M DTT and increase of 600 nm absorbance at 30ºC was recorded for 30 min. The
second assay used thioredoxin reductase and NADPH as electron donors for
thioredoxin and was performed essentially as described elsewhere (Spyrou et al.
1997). Briefly, aliquots of Sptrx-2 and D Sptrx-2 were preincubated at 37 °C for 20 min
with 2 m l of: 50 mM Hepes, pH 7.6, 100 m g/ml bovine serum albumin, and 2 mM DTT
in a total volume of 70 m l. This step allows total reduction of the protein. Then, 40 m l
of a reaction mixture composed of 200 m l of Hepes (1 M), pH 7.6, 40 m l of EDTA (0.2
M), 40 m l of NADPH (40 mg/ml), and 500 m l of insulin (10 mg/ml) were added. The
reaction was initiated by the addition of 10 m l of thioredoxin reductase from calf
thymus (3.0 A412 unit), and incubation was continued for 20 min at 37 °C.  The
reaction was stopped by the addition of 0.5 ml of 6 M guanidine-HCl, 1 mM DTNB,
and the absorbance at 412 nm was measured. In both assays human Trx-1 was used
as control.
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Human Sptrx-2 in situ hybridization analysis: Riboprobes (sense and
antisense) were generated from Sptrx-2 ORF template using MEGAscript-II
transcription kit (Ambion, Austin, TX). Probes were labelled with digoxigenin-UTP
(Boehringer Mannheim, Mannheim, Germany). Paraffin sections of human testis and
human multi tissue slides (T1065; Dako, Copenhagen, Denmark) were deparaffinized
with xylene and rehydrated with ethanol and air dried.  Sections were hybridized for
18 h at 55˚C with the labelled probes diluted in hybridization buffer (4 x SSC, 50%
formamide, 1x Denhardt´s solution, 1% sarcosyl, 10% dextran sulphate and
250µg/ml yeast RNA). Sections were subsequently washed twice in 2 x SSC at room
temperature, 0.5 x SSC at 60˚C and in 0.1 x SSC at 60˚C for 15 min, each. Then the
tissues were incubated with alkaline phosphatase conjugated anti-digoxigenin
antibody (dil. 1:750; Boehringer Mannheim) for 2 h. The signal was visualized using
Vector Alkaline Phosphatase kit-II (Vector Laboratories, Burlingame, CA) and the
sections were mounted. Images were taken with Nikon FXA microscope equipped
with PCO Sensicam digital camera (PCO, Kelheim, Germany) and the images were
processed with CoralDraw9 software (Corel Corporation Ltd., Ontario, Canada).
Preparation of spermatozoa and extraction of sperm proteins. Semen samples
from healthy donors were allowed to liquefy at room temperature and separated
from seminal plasma by centrifugation (1000 x g) for 10 min at room temperature.
After two washes in PBS the pelleted spermatozoa were frozen at -20°C until use.
The sperm pellet was solubilized in a lysis buffer containing Tris-HCl 0.1 M pH 8.0,
NaCl 0.15 M, protease inhibitor cocktail (Boehringer Mannheim) and phosphatase
inhibitor cocktail (SIGMA) at the concentration recommended by the manufacturers.
Samples were then subjected to three cycles of freezing/thawing in dry ice-ethanol,
incubated for 30 min on ice and centrifuged at 14000 rpm for 30 min. The soluble
fraction was used for further analysis.
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Antibody production, immunoblotting analysis and immunocytochemistry.
Purified GST-hSptrx-2 was used to immunize rabbits (Zeneca Research
Biochemicals). After six immunizations, serum from rabbits was purified by
ammonium sulfate precipitation. Affinity purified antibodies were prepared using a
cyanogen bromide-activated Sepharose 4B column, onto which 0.5 mg recombinant
Sptrx-2 fragment had been coupled using the procedure recommended by the
manufacturer (Pharmacia). Specificity of the antibodies was tested by western
blotting using recombinant Sptrx–2 and total cell extracts. Immunodetection was
performed with horseradish peroxidase-conjugated donkey anti-rabbit IgG diluted
1:5000 following the ECL protocol (Amersham Corp.). For immunocytochemistry,
paraffin sections containing multiple human tissues (T1065, Lot: 9994A) were
obtained from Dako (Copenhagen). In addition routine paraffin sections of human
testis were used. For immunofluorescence analysis human sperm samples were
obtained from healthy volunteers. Immunocytochemistry was performed as
described previously (Rybnikova et al. 2000) either by the ABC-method or by indirect
immunofluorescence method using goat anti-rabbit-FITC (1:100, 30 min, Boehringer-
Mannhein) as a secondary antibody. The fluorescence samples were embedded in
PBS-glycerol mixture containing 0.1% p-phenylenediamine. The sections were
examined with Nikon Microphot-FXA microscope equipped with proper fluorescent
filters.
Green fluorescent protein analysis. We used the pEGFP-N3 vector (Clontech)
to express the GFP at the C-terminus of hSptrx-2. For that purpose we used the
mutagenic primers GFP-F1 (5'-GTTGAATTCGCCACCATGGCAAGCAAAAAAC-3´)
as forward primer and GFP-R1 (5'-GTTTTCCTCAGGATCCCTCAAAGAGTCTATT-
3') as reverse primer to amplify human Sptrx-2 from pGEM-T/hSptrx-2. The forward
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primer introduces an EcoRI site followed by a Kozac sequence (Kozak 1996) and the
reverse primer introduces a BamHI site. The amplified DNA was cloned into the
EcoRI-BamHI sites of pEGFP-N3 expression vector and E. coli XL1-Blue strain was
transformed with the recombinant plasmid, pGFP-hSptrx-2. The plasmid was
purified using the midi-prep kit (Qiagen, Chatsworth, CA) and sequenced.
Transfection was performed with 1 m g of DNA diluted in 10 m l of H2O and 0.5 m l
of 0.1 M PEI. The mixture was mixed thoroughly, incubated at room temperature for
10 min and subsequently added to the medium and applied onto HEK293 cells
grown in coverslips. 48 hours after transfection cells were fixed with 3.7%
paraformaldehyde for 20 min at room temperature. The nucleus was stained with 1
m M 7-aminoactinomycin D (7-AAD) (Molecular Probes) for 30 min.
The GFP pictures were acquired with a Leica laser scanning confocal
microscope. For GFP excitation we used the 488 line of an ArKr laser and emitted
light was collected between 500 and 540 nm. 7-AAD was excited with the 568 line
and emitted light was collected between 640 and 680 nm.
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LEGENDS TO THE FIGURES
Fig. 1. Nucleotide and amino acid sequence of human Sptrx-2. The nucleotide
numbers are displayed on the right and the amino acid numbers on the left. The two
stop codons in frame within the 5´-UTR are underlined. The internal PEST sequence
and the polyadenylation signal AATAAA are double underlined. The conserved
thioredoxin active site and the two putative NDP kinase active site motifs are boxed.
Fig. 2. A) Organization of human Sptrx-2 protein. Numbers refer to those of
the amino acid sequence shown in Figure 1. B) Alignment of the predicted amino
acid sequence of Sptrx-2 thioredoxin domain with all the known human members
of the thioredoxin family. Alignment was performed using the W-Clustal program
included in the DNASTART package (Thompson et al. 1994). Identical residues are
shadowed and thioredoxin active site sequence CGPC is shown in bold and boxed.
Numbers are referred to those of human Trx-1 (Wollman et al. 1988).
Fig. 3. A) Phylogenetic analysis of all the members of the human thioredoxin
family. The phylogenetic analysis was produced by applying the neighbour-joining
method of Saitou and Nei to the alignment data (Saitou & Nei 1987). The scale
indicates the number of amino acid substitutions per hundred residues. B)
Percentage of similarity of human thioredoxins. The data are derived from the
protein alignment performed in Figure 2 using the same software package.
Fig. 4. Expression pattern of human Sptrx-2 mRNA. Human multiple tissue
poly(A)+ mRNA blots (Clontech) were hybridized with the Sptrx-2 ORF probe
identifying only one mRNA species at 2.4 kb in testis. A long-term exposure of the
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blots was necessary to have enough signal. b -actin was used as control to determine
the relative amount of mRNA from each tissue. P.B.L., peripheral blood leukocytes.
Fig. 5. In situ hybridization analysis of human Sptrx-2 mRNA distribution.
Human testis section hybridized with digoxigenin labelled Sptrx-2 antisense probe.
Signal can be seen in late primary spermatocytes (arrowheads) and in round
spermatids (arrows). The rest of the testicular cells are devoid of signal. Bar
represents 30m m (A), 15 m m (B) and 10m m (C, D).
Fig. 6. Expression and purification of human recombinant Sptrx-2 protein.
Full length human Sptrx-2 and a truncated form expressing only the N-terminal
thioredoxin domain, D Sptrx-2, were purified as GST fusion protein and thrombin
cleaved with 5 U/mg protein. On inset, both proteins (4 m g) were separated by SDS-
PAGE 12%, Lane 1 Sptrx-2, Lane 2 D Sptrx-2. On chromatogram, full length Sptrx-2
was run on a gel filtration chromatography column with the following markers: a)
Albumin, b) Ovalbumin, c) Chymotrypsinogen A and d) Ribonuclease A.
Fig. 7. Enzymatic activity of human Sptrx-2. Purified Sptrx-2 and D Sptrx-2
were assayed for its ability to reduce insulin disulfide bonds using DTT as electron
donor: (O) Trx-1 at 5 m M, (q) D Sptrx-2 at 25 m M, ( D ) D Sptrx-2 at 5 m M, (    ), Sptrx-2 at
25 m M. The reaction was initiated by adding 1 m l of 100 mM DTT and followed for 30
min at 30ºC.
Fig. 8. Tissue and cellular distribution of human Sptrx-2 protein. (A) Sptrx-2
expression in different human tissues and cell lines. All extracts were at 10 m g except
sperm at 1 m g. (B) Immunocytochemistry of human testis showing strong Sptrx-2
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labeling in the apically localized spermatids (black arrowheads) and spermatozoa
tails (white arrowheads). Spermatogenic cells at earlier stages of development and
Leydig cells are devoid of staining. Image is at 20x amplification. (C)
Immunofluorescent demonstration of Sptrx-2 in human ejaculated spermatozoa.
Labeling is present from the postacrosomal region and the neck through the middle
and principal piece. The anterior part of the head is unlabeled. Bar represents 4 m m.
Fig. 9. Subcellular distribution of human Sptrx-2 protein. (A) HEK 293 cells
transfected with Sptrx-2/GFP construct show green fluorescence mostly in the
cytosol although some diffuse signal is also found scattered through the nucleus. (B)
The same cells were stained further with the DNA-selective dye 7-AAD, resulting in
a red staining of nuclear and mitochondrial DNA. (C) Overlapping of both images
demonstrates co-localization of both signals (yellow color) only in some spots in the
cytosol and in the perinuclear region, indicating mitochondrial localization. In
addition, there is a diffuse yellow staining within the nucleus. Micrographs were
obtained from a single focal section.
TABLE I. Genomic organization of human Trx7 gene.
Exon size Intron size Sequence at exon/intron junctionResidue at junction Coding information
Exon (bp) Intron (bp) 5´splice donor 3´splice acceptorAA Position Type
1 >63 5´-UTR
2 40 1 1.203 TTTGTgtaag gatagTAGAT 5´-UTR / Trx
3 58 2 78 TACAGgtggg tgcagACAGT Q/T 11/12 0 Trx
4 107 3 193 AACAGgtata tctagTGATT V 31 1 Trx
5 72 4 6.538 CTGTCgtaag tccagGCAGA V/A 66/67 0 Trx
6 117 5 4.682 GTGTTgtaag tatagAATGG V/N 90/91 0 Trx
7 67 6 1.251 CTCAGgtaat catagTATCC Q/Y 129/130 0 Interface
8 74 7 885 TGTTCgtaag tccagAGGAA Q 152 1 Interface
9 93 8 1.103 GAAAAgtaag tgaagATTAC K/I 176/177 0 NDPk-A
10 196 9 2.084 ACCAGgtatg tgtagTGTGA Q/C 207/208 0 NDPk-A
11 176 10 8.933 GACAGgtata gacagTTTAC S 273 2 Interface
12 145 11 7.295 GAAAGgtagg tttagATGAT D 332 1 NDPk-B
13 108 12 697 ACCAGgtaga aatagTGGTC S 380 2 NDPk-B
14 152 13 3.024 GAGAGgtagg caaagTTTAT S 416 2 NDPk-B
15 145 14 6.037 AAGAGgtaaa cttagAGCAG E 467 1 NDPk-C
16 238 15 2.295 TCTGTgtaag tgcagGGGTC V 515 2 NDPk-C / 3´-UTR
17 >156 16 3.136 GTGAAgtagc cctagAACTT 3´-UTR
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